Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 9/20 | 0.68 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.68 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.68 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.68 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | USP2 | O75604 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CASP7 | P55210 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | MDM4 | O15151 | 1/20 | 0.54 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.54 |
| ▸ | VDR | P11473 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1654288 | 0.90 | GPBAR1 (0.76) | GPBAR1NR1H4PDE3ATBXA2RSLC10A2 | |
| SCHEMBL21594795 | 0.90 | GPBAR1 (0.76) | GPBAR1NR1H4PDE3ATBXA2RSLC10A2 | |
| SCHEMBL7756845 | 0.90 | GPBAR1 (0.76) | GPBAR1NR1H4PDE3ATBXA2RSLC10A2 | |
| SCHEMBL21631677 | 0.90 | GPBAR1 (0.76) | GPBAR1NR1H4PDE3ATBXA2RSLC10A2 | |
| SCHEMBL3447484 | 0.90 | GPBAR1 (0.76) | GPBAR1NR1H4PDE3ATBXA2RSLC10A2 | |
| SCHEMBL7996290 | 0.87 | GPBAR1 (0.72) | GPBAR1NR1H4PDE3ATBXA2RSLC10A2 | |
| SCHEMBL4431263 | 0.86 | GPBAR1 (0.70) | GPBAR1NR1H4PDE3ATBXA2RSLC10A2 | |
| SCHEMBL1635362 | 0.86 | GPBAR1 (0.71) | GPBAR1NR1H4PDE3ATBXA2RSLC10A2 | |
| SCHEMBL4281815 | 0.85 | GPBAR1 (0.69) | GPBAR1NR1H4PDE3ATBXA2RSLC10A2 | |
| SCHEMBL1492140 | 0.83 | GPBAR1 (0.66) | GPBAR1NR1H4PDE3ATBXA2RSLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125029-B1 | CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS | LIPOCALYX GMBH (DE) | 2016-10-12 | — | — | EP | disclosed |
| US-20130011916-A1 | CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS | LIPOCALYX GMBH (DE) | 2013-01-10 | — | — | US | disclosed |
| US-8193246-B2 | Lipids and lipid assemblies comprising transfection enhancer elements | MARINA BIOTECH, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| EP-2125031-A2 | LIPIDS AND LIPID ASSEMBLIES COMPRISING TRANSFECTION ENHANCER ELEMENTS | Novosom AG (DE) | 2009-12-02 | — | — | EP | disclosed |
| US-20080306153-A1 | Lipids and lipid assemblies comprising transfection enhancer elements | CEQUENT PHARMACEUTICALS, INC. | 2008-12-11 | — | — | US | disclosed |
| EP-1938843-A1 | Lipids and lipid assemblies comrising transfection enhancer elements | Novosom AG (DE) | 2008-07-02 | — | — | EP | disclosed |
| WO-2008074487-A2 | LIPIDS AND LIPID ASSEMBLIES COMPRISING TRANSFECTION ENHANCER ELEMENTS | NOVOSOM AG (DE) | 2008-06-26 | — | — | WO | disclosed |
| EP-1935434-A1 | Construction and use of transfection enhancer elements | Novosom AG (DE) | 2008-06-25 | — | — | EP | disclosed |
| US-20080145413-A1 | Lipids and lipid assemblies comprising transfection enhancer elements | MARINA BIOTECH, INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080145413-A1 | Lipids and lipid assemblies comprising transfection enhancer elements | HNRNPH3, SREBF2, PHOSPHO1 | GPBAR1 3857/4885NR1H4 1583/4885PDE3A 4775/4885 |
| US-20080306153-A1 | Lipids and lipid assemblies comprising transfection enhancer elements | SREBF1, SREBF2, ELOVL1 | GPBAR1 1497/4885NR1H4 561/4885PDE3A 3045/4885 |
| US-20130011916-A1 | CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS | TEAD4, CREB1, ELF3 | GPBAR1 1385/4885NR1H4 880/4885PDE3A 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.